cyrilzakka/clinical-trials huggingface dataset:
A Comparison of Kinesio® Taping Methods for Subjects With Patellar Tendonitis

The purpose of this study is to explore the possible effects Kinesio Tape may have on proprioception in individuals with patellar tendonitis. A supportive knee application, a facilitative hip application, and a combination of the two will be applied and compared. Within and between group comparisons will be drawn.

Participants will report for two research sessions with 24-36 hours between. Prior to arrival, they will complete a digital Victorian Institute of Sport Assessment for Patellar Tendonitis (VISA-P) and email it to the researcher. Participants must score less than 80 (out of a possible 100) to be considered for this study. If the individual meets the inclusion criteria, he/she will be scheduled for the 1st session. Upon arrival to the first session, informed consent will be obtained, the VISA-P will be reviewed, and intance of patellar tendonitis will be confirmed through palpation. Participants will then completed a Tampa Scale for Kinesiophobia (TSK) to measure fear of movement and a Visual Analog Scale (VAS) to measure overall pain. Height and weight measurments will be taken due to requirements of the Biodex Balance System (BBS), which will be used for balance measurements. Participants will take two, twenty-second practice tests, one with eyes open and one with eyes closed, followed by two minutes rest. Baseline testing will then be completed as follows: the participant will complete two tests with eyes open, and two tests with eyes closed on the injured leg, each with one minute rest between. The participant will then be taped with Kinesio Tape to either the hip, knee, or both the hip and knee according to the random group assignment. They will then rest for 15 minutes and complete a second round of balance testing with the same parameters as baseline testing. Participants will be scheduled for a second day no less that 24 hours and no more than 36 hours for re-test purposes.

On the second day of testing, participants will be given $10 for their participation on Day 1. If they want to continue with testing procedures, they will participate in the same balance testing procedures as Day 1. The integrety of the tape application will be confirmed, and second TSK and VAS scale will be administered. A final round of balance testing will be completed, and the participant will receive an additional $10 if they choose to complete both days of testing.

This research will allow us to compare results of the TSK, the VAS and the BBS testing both within subject and between group.


Eligibility Criteria:
Inclusion Criteria:

* score of less than 80 on the Victorian Institute of Sport Assessment for Patellar Tendonitis (VISA-P)
* experienced patellar tendon pain for greater than 14 days
* tender to palpation at the patellar tendon.

Exclusion Criteria:

* knee surgery in the last six months
* acute injury to the knee
* any pain in the ankles, hips or core that may compromise balance testing
* any allergy to adhesive
* malignancies
* cellulitis
* skin infection
* diabetes
* fragile skin
Low-level Laser Therapy for the Treatment of Diabetic Foot Ulcer

The study evaluates the efficacy of Low-level laser therapy on ulcer healing in patients with diabetic foot ulcer. Half the patients are randomized to receive Low-level laser therapy and a half to recieve the placebo (LED).

Low-level laser therapy(LLLT) has been reported to aid ulcer healing in patients with diabetic foot ulcer. However, patients need to come to hospital to receive LLLT performed by medical professional. The LLLT shoe has been developed for home using. Patients can wear LLLT shoe 30 min once daily instead of going hospital for LLT therapy. The aim of this study is to see whether LLLT shoe helps with healing compare with placebo (LED shoe).

Eligibility Criteria:
Inclusion Criteria:

* Patients with chronic diabetic foot ulcer
* Ankle brachial index ≥ 0.4
* Toe pressure brachial index ≥ 0.3
* Transcutaneous oxygen measurement (TCOM) ≥ 40 mmHg
* Ulcer size less than 25 cm2

Exclusion Criteria:

* Infected ulcer
* Fever
* HbA1C \> 15 %
Green Tea Mouthwash on Generalized Plaque- Induced Gingivitis

This investigation will study the effect of green tea mouthwash as an adjunctive therapy to mechanical treatment on gingival health, and whether it has any side effects. This study also aims at increasing the awareness among health professionals and the community regarding the benefits of natural herbal products such as green tea on oral health, opposed to common chemical products. This may provide an efficient alternative for people who are sensitive to certain chemical products or who have limited sources of income and cannot afford expensive treatment of dental problems.


Eligibility Criteria:
Inclusion Criteria:

* Patients attending the clinics at the Taibah University Dental College and Hospital (TUDCH)
* Age from 18 - 35 years
* Generalized plaque-induced gingivitis (GBI \> 85%)

Exclusion Criteria:

* Patients with any systemic diseases
* Patients under regular medication (e.g. Contraceptives, Hormone- Replacement Therapy)
* Pregnant or breast-feeding patients
* Smokers
* Periodontitis patients
* Patients who received any form of periodontal therapy within the last 6 months
* Patients who were under antibiotic therapy the past month
* Patients using regular mouthwash or other chemical plaque control agents (e.g. Miswak) except for regular toothpaste (Note: toothpastes with specific anti-inflammatory properties are excluded)
Oral Tranexamic Acid and Laser for Treatment of Melasma

Tranexamic acid and 1927 diode laser non-ablative fractionated laser for the treatment of Melasma.

Seeking healthy non-smoking male and female volunteers of all skin types of age 18 to 50 with moderate melasma or severe melasma. Participants will receive up to 5 monthly laser treatments to half the face and need to take a pill twice a day for 4 months. Follow up visits are required 1 month, 3 months and 6 months after the final treatment. Compensation of up to $150 will be provided based on completed visits.

Eligibility Criteria:
Inclusion Criteria:

Age 18 to 50 Skin types I through VI (all skin types) Moderate or severe melasma

Exclusion Criteria:

Pregnant or nursing women Current use of hormonal birth control medication or any hormonal therapy Use of topical steroids within 1 month of study enrollment Use of topical hydroquinone within 3 months of study enrollment History of laser or dermabrasion to the face within 6 months of study enrollment Regular use of tanning parlors Occupation involving primarily outdoor activities Current treatment with blood thinning medications History of thrombosis or thrombophilia History of thromboembolic disease, such as deep vein thrombosis, pulmonary embolism and/or cerebral thrombosis Family history of thromboembolic disease History of stroke History of \>2 spontaneous abortions History of kidney dysfunction History of cancer Smoking Significant cardiovascular or respiratory disease (end-stage congestive heart failure or chronic obstructive pulmonary disease) History of subarachnoid hemorrhage History of acquired disturbances of color vision Known allergy to tranexamic acid As per the investigator's discretion, any physical or mental condition which might make it unsafe for the subject to participate in this study
Artificial Intelligence in Lung Cancer Screening

Single-center, non-profit, observational, retrospective study of collection of clinical and amnestic data and images to create, implement and develop a pilot model of an integrated virtual platform.

The project we propose is a study whose objective was to develop an artificial intelligence program integrated into a web-based platform for the optimization of the performance of lung cancer screening for the diagnosis of lung nodules and risk stratification in subjects exposed to environmental carcinogens and/or cigarette smoke.

Inclusion criteria:

Age \&gt; 50; smokers for at least 20 pack-years (20 cigarillos a day for 20 years) or former heavy smokers if they quit less than 15 years ago; and/or previous professional exposure to asbestos; absence of lung cancer symptoms; who performed lung cancer screening after the year 2000 upon approval of the study by the relevant EC.

Eligibility Criteria:
Inclusion Criteria:

* Age \&gt; 50 years;
* smokers for at least 20 pack-years (20 cigarettes a day for 20 years) or former heavy smokers if they quit less than 15 years ago;
* and/or previous professional exposure to asbestos;
* absence of lung cancer symptoms;
* who performed lung cancer screening after the year 2000 upon approval of the study by the relevant Etical Committee

Exclusion Criteria:

* Age \&lt; 50 years
* never smokers
* lung cancer symptoms
Evaluation of the QuantiFERON-TB Test.

To compare the results of the investigational test to the currently approved QuantiFERON-TB Gold In-Tube test.

The objective of the study was to enroll patients who have clinical signs/symptoms strongly indicating TB and who are receiving of have to start the treatment for active TB, and test the variants of the CST001 assay to support the evaluation of clinical sensitivity.

Eligibility Criteria:
Inclusion Criteria:

* Clinical symptoms consistent with a high probability of having TB disease
* Receiving, or are likely to receive, therapy for active TB
* Confirmed tuberculosis by either AFB smear and culture testing, or Nucleic Acid Amplification methods and culture testing.
* Between 18 and 70 years of age.

Exclusion Criteria:

* Taken therapy for active TB or latent TB for more than 14 days
* Culture confirmation of M. tuberculosis not obtained
Immuno-pet IMaging ResPonses AdministeRed Immune CheckpoiNt InhibiTor

This study investigates whether a single subcutaneous administration of anti-PD-1 antibody can induce CD8+ T-cell tumor-infiltration that can be non-invasively monitored with \[89Zr\]crefmirlimab berdoxam PET imaging as an imaging biomarker.

This is a two-armed open-label feasibility study with exploratory endpoints, where subjects are participating for 2 years after completement of enrollment to determine disease-free survival rates. The therapeutic intervention is a single subcutaneous administration of the humanized hinge region-stabilized IgG4 monoclonal anti-PD1 antibody PF-06801591 (sasanlimab) in a fixed dose of 300 mg in a neo-adjuvant setting, with or without radiation therapy, followed by curative-intended surgery. The diagnostic intervention is a radiolabeled imaging tracer \[89Zr\]Zr-crefmirlimab berdoxam that entails two intravenous administrations of a fixed dose of 1.5 mg protein dose labelled with activity dose 37 MBq Zirconium-89; one at baseline and one at 2 weeks after sasanlimab injection, to visualize CD8+ T-cells in vivo.

Eligibility Criteria:
Inclusion Criteria:

* Age \>50 years
* Histologically or cytologically proven adenocarcinoma or squamous cell lung cancer
* Primary tumors \>1 cm and \</= 5 cm largest diameter
* Scheduled for curative surgery
* Informed consent
* Adequate bone marrow function (ANC \>/= 1500, platelets \>/=100k, Hgb \> 9), renal function (CLCr \>30 mL/min), liver function (TotalBili \</= 1.5 x ULN; AST and ALT \</=2.5 x ULN).

Exclusion Criteria:

* Inability to undergo SPECT or PET scans
* Pleiomorphic, lepidic, mucinous or large cell neuro-endocrine histological subtypes of non-small cell lung carcinoma
* Histologically confirmed druggable mutation (EGFR, RET, ROS, ALK, BRAF V600, NTRK, NRG1, MET ex14Sk)
* Pregnancy or lactation
* Active infection, auto-immune disease, prior organ-transplantation or haematological condition that requires medication that potentially interferes with immune cell activation.
* Documented medical history of auto-immune disease, organ-transplantation or haematological condition that potentially interferes with immune cell behavior
* Prior radiation therapy to the chest
* Splenectomy
* Enrolled in a current investigational drug trial
MESA Treatment for NK/T Cell Lymphoma

Study on the efficacy and safety of MESA chemotherapy for treating NK/T cell lymphoma

Extranodal natural killer (NK)/T-cell lymphoma (ENKTL), nasal type, is a distinct and heterogeneous histopathologic subtype of non-Hodgkin lymphoma (NHL), accounting for 5%\~10%. The frequency of ENKTL among NHL patients is significantly higher in Asia than in Western countries. Despite radiotherapy and chemotherapy, the prognosis for ENKTL patients is poor, with 5-year median survival time for primary nasal site was 5 years, for non-nasal extranodal sites 6 months. ENKTL is so aggressive and has high mortality rate and till now there is no standard therapy. In recent years SMILE chemotherapy has clinical efficacy and is one of first line therapy for ENKTL. However it is apparent that this regimen is extremely toxic with grade 4 neutropenia especially for Asian patients. On these grounds, new therapy MESA is used for Asian patients with ENKTL in order to achieve good efficacy and safety.

Eligibility Criteria:
Inclusion Criteria:

* Pathological diagnosis is NK/T cell lymphoma；
* At least one objective evaluation ( measurable ) lesions
* Age 15 \~ 60 years old, men and women are not limited
* ECOG(Eastern Cooperative Oncology Group）performance status 0\~3，Expected to survive more than 3 months;
* Heart, kidney function in the normal range
* Liver function: transminase\< 2 times the normal value
* pregnancy tests of women childbearing age must be negative; Men and women agree to use effective contraception during the treatment and the following year
* Before the test sign the written informed consent

Exclusion Criteria:

* The early use of methotrexate or/and L-asparaginase;
* Pregnant or nursing, psychiatric patients complicated with malignant tumor
* At the same time the application of other trial drug, drug contraindications exist in research;
* Serious infection or metabolic diseases
* Liver dysfunction, serum direct bilirubin, indirect bilirubin, transaminase 2 times higher than normal; serum total protein or albumin below normal;
* Renal insufficiency, creatinine clearance rate was 2 times higher than normal, especially the creatinine clearance rate is less than 30ml/min;
* Before entering the group, blood: White blood cell\< 3×10E9/L; absolute neutrophil count\<1.5×10E9/L; platelet\<100×10E9/L ( bone marrow is not violated ); platelet count \<75×10E9/L ( bone marrow invasion ); hemoglobin\<100g/L.
* In the 6 months before entering the group, patients with uncontrolled or serious cardiovascular diseases, including myocardial infarction, III-IV class heart failure, uncontrolled angina or clinically significant pericardial disease, and diabetes and phlebitis;
* HIV antibody positive, HBsAg positive after antiviral HBV(hepatitis B virus) DNA titer in 104copies/ml the following groups. HIV antibody positive, HBsAg+ and DNA titer in 104copies/ml after antiviral HBV therapy
* Coagulation abnormalities.
Astym® Compared Eccentric Exercise for Chronic Mid-substance Achilles Tendinopathy

The purpose of this study is to compare the changes in pain and self-perceived function between two different treatments for Achilles tendinopathy: the Astym® protocol (a form of soft tissue mobilization using instruments) and a specific exercise protocol that involves strengthening the calf and Achilles tendon. Astym® (A-stim) is not an acronym, but rather stands for "A Stimulation" of the body's healing response, describing the physiologic process which occurs with Astym treatment. Astym is the trademark name of a non-invasive treatment where instruments are applied topically to locate unhealthy soft tissue, and to transfer mild to moderate pressure to the underlying soft tissue structures. The aim of Astym treatment is to eliminate scar tissue and stimulate tissue regeneration. Both the principal investigator and co-investigator have been trained and certified in administering the Astym treatment. The specific exercise protocol will involve exercises that strengthen the Achilles and calf through eccentric exercise. Eccentric exercise is a form of exercise where the benefit comes from applying a controlled lengthening stress to the muscle and tendon.


Eligibility Criteria:
Inclusion Criteria

* Pain for 3 months or longer in the mid portion of only one Achilles tendon.
* Must read, speak and understand English

Exclusion Criteria

* Previous surgery to the Achilles tendon that is currently painful
* An injection into the Achilles tendon in the previous 4 weeks
* Have symptoms in both Achilles tendons concurrently
* Have taken fluoroquinolone antibiotics in the past 6 months
Rapid HIV Testing for Emergency Department Patients

The purpose of this study is to test data collection options in emergency departments (EDs) and to enhance ED patient awareness of the risk of HIV infection.

Rapid HIV testing is a new technology that speeds receipt of HIV test results. Its use in EDs has been demonstrated, but patient acceptance of rapid testing in the ED has not been optimal. It is likely that the low acceptance is partially due to ED patients not realizing the risk of acquiring an HIV infection or the importance of knowing their HIV status. The purpose of this study is to test data collection options in EDs and to enhance ED patient awareness of the risk for HIV infection.

This three phase study will take place at the Rhode Island Hospital Emergency Department. Each participant will be followed for the duration of their ED visit.

In Phase I, the proportion of participants who are willing to undergo rapid HIV testing in the ED will be measured. Additionally, the HIV testing history of these participants, their reasons for undergoing testing or for never having been tested for HIV, and factors associated with acceptance or decline of testing and history of HIV testing will be determined. An educational video will be developed and used to investigate its effectiveness in convincing participants to have the rapid HIV test. All participants agreeing to undergo a rapid HIV test will receive a survey to complete.

In Phase II, a questionnaire and feedback tool to make participants aware of their risk for an HIV infection through injection drug use and sex will be developed and investigated.

In Phase III, the questionnaire and feedback tool developed in Phase II will be used to determine whether or not making participants aware of their risk for an HIV infection increases their acceptance of being tested for HIV in the ED. Participants in Arm 1 will receive the questionnaire and feedback tool while participants in Arm 2 will not.

Eligibility Criteria:
Inclusion Criteria:

* English-speaking
* Subcritical illness or injury

Exclusion Criteria:

* Critical illness or injury
* Mental or physical disability
* Known HIV infection
* Participation in an HIV vaccine study
* Prison inmate
* Acute psychiatric illness that, in the opinion of the investigator, would prevent the participant from completing the study
Is There a Digital Divide in Chronic Kidney Disease (CKD)?

This study is looking to improve the safety of patients with chronic kidney disease via education provided on a mobile tablet. This study will additionally examine if electronic tools, such as mobile tablets, can help.

Individuals with CKD are at risk for adverse safety events, yet little is known regarding the utility of health information technology (IT) educational tools to reduce these events. The results of this project will be invaluable in gaining a better understanding of the limitations and potential for use of a patient-centered mHealth patient safety educational intervention in high-risk individuals with CKD.

The study will evaluate the perceived eHealth literacy of patients with CKD and its relation to medication errors in the CRIC cohort. The hypothesis is that a novel mHealth-based patient safety curriculum designed to address a wide-range of e-literacy will be effective in attenuating the identified Digital Divide adversely affecting many CKD patients, and will reduce adverse safety events common in this population.

Study Aims:

1. Examine the association between surveyed perceived e-literacy and medication errors in individuals with CKD

   Hypothesis 1: Medication error rates will be higher among CRIC participants with low eHealth literacy.
2. Assess the acceptance and feasibility of a novel mHealth-based patient safety curriculum to improve patient safety risk knowledge among individuals with CKD and determine its efficacy in increasing patient safety risk awareness.

Hypothesis 2a: A low literacy mHealth patient safety curriculum will improve patient safety risk awareness among high risk individuals with CKD.

Hypothesis 2b: Medication error rates will be higher among CRIC participants with low patient safety risk awareness.

Eligibility Criteria:
Inclusion Criteria:

* Enrolled in Chronic Renal Insufficiency Cohort (CRIC) Study.

Exclusion Criteria:

* Not enrolled in Chronic Renal Insufficiency Cohort (CRIC) Study.
Influenza 2020/2021

As part of the fight against COVID-19, the UK government has announced its most comprehensive flu campaign to date (https://www.gov.uk/government/news/most-comprehensive-flu-programme-in-uk-history-will-be-rolled-out-this-winter). This should not be surpising: every year NHS hospitals experience an overwhelming number of influenza cases, and COVID-19 increases this concern. As in previous years, the flu vaccine is free at the point of care for people 65 and over. New this year is that later in the season the vaccine will be made available free at the point of care for people 50 and over. However, if people refuse to take the vaccine this comprehensive program cannot benefit public health.

The degree to which vaccine hesitancy is expressed varies across characteristics of the vaccine considered and the time and place it is offered, and across characteristics of the person's perceptions of complacency, convenience, confidence, calculations, and communal responsibility, i.e. the "5Cs". Information campaigns can be used to influence all 5Cs, and public facing information is often a necessary component of public health campaigns that may also include structural components. Largely, information campaigns can be viewed as a type of educational intervention.

Educational interventions may fall short of what is needed to alter people's intentions to vaccinate where they focus on system 1 rational thinking processes and neglect system 2 automatic thinking processes. To be more effective, public health messages must be tailored to align with the "beliefs, attitudes, and motivations" of the very people they intend to influence.

Fact-led educational interventions to increase parents' intentions to vaccinate their children are particularly ineffective where more subtle content opposes the recipient's deep-seated values. In a different context, recycling behaviour, previous research demonstrated that messages aligned with people's deep-seated values (i.e. the moral foundations that underlie political ideologies) are more likely to promote desired behavioural intentions than unaligned messages.

The present research expands the scope of previous research in two ways. First, rather than investigating parental attitudes towards vaccination, the investigators will look at people's intentions to self-vaccinate. Second, the investigators will explore the effectiveness of messages aligned with the moral foundations that underlie individual's political ideologies on their intentions to be vaccinated.


Eligibility Criteria:
Inclusion Criteria:

* Resident in England
* Age 50+ years old, inclusive

The age criteria is set at 50+ years old, because this is the age group currently being advised by Public Health England to seek the flu jab as soon as possible this season. (https://www.gov.uk/government/news/most-comprehensive-flu-programme-in-uk-history-will-be-rolled-out-this-winter).

Exclusion Criteria:

* Not a resident in England
* Age less than 50 years old